A multicenter, observational study assessing overall survival in patients with metastatic breast cancer treated with first line paclitaxel with or without bevacizumab

Trial Profile

A multicenter, observational study assessing overall survival in patients with metastatic breast cancer treated with first line paclitaxel with or without bevacizumab

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Jul 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Paclitaxel (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Jul 2016 New trial record
    • 07 Jun 2016 Results assessing the overall survival of patients with HER2-negative metastatic breast cancer presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top